Eli Lilly and Company
Tirzepatide
Type 1 Diabetes
Countdown
146days
Phase 3 readout · ~ Nov 30, 2026 estimated
What's at stake
Phase 3 trial results for Tirzepatide in Type 1 Diabetes are due ~ Nov 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· ClinicalTrials.gov
verified 15h ago
“CT.gov NCT06962280: Phase 3 trial, sponsor Eli Lilly and Company, drug Tirzepatide. Primary completion date 2026-11 (estimated).”